Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,127
Total Claims
$6.2M
Drug Cost
716
Beneficiaries
$8,721
Cost/Patient
Risk Score Breakdown 25/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+122%
Cost per patient vs peers
$8,721 vs $3,933 avg
+41%
Brand preference vs peers
71.9% vs 51.2% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.3%
Opioid Rate
27
Opioid Claims
$6,616
Opioid Cost
74.1%
Long-Acting Rate
Brand vs Generic
Brand: 6,707 claims · $6.1M
Generic: 2,620 claims · $56K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 1,116 | $1.3M |
| Insulin Aspart | 627 | $621K |
| Empagliflozin | 705 | $600K |
| Dulaglutide | 427 | $569K |
| Insulin Glargine/Lixisenatide | 362 | $362K |
| Empagliflozin/Metformin Hcl | 338 | $308K |
| Dapagliflozin Propanediol | 360 | $305K |
| Insulin Lispro | 274 | $260K |
| Insulin Glargine,hum.Rec.Anlog | 315 | $173K |
| Liraglutide | 91 | $139K |
| Insulin Detemir | 200 | $122K |
| Insulin Aspart Prot/Insuln Asp | 158 | $121K |
| Dapaglifloz Propaned/Metformin | 135 | $98K |
| Exenatide Microspheres | 98 | $87K |
| Insulin Lispro | 47 | $77K |
Prescribing Profile
Patient Profile
71
Avg Age
49%
Female
1.70
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About